Diabetic nephropathy. Is renoprotection determined by the choice of hypoglycemic therapy?

by A. Y. Babenko, V. K. Bayrasheva
Published 2015-12-01

HYPERHOMOCYSTEINEMIA AND DIABETIC NEPHROPATHY: THE INFLUENCE OF GENETIC FACTORS, CLINICAL AND PATHOGENIC INTERRELATIONS WITH INFLAMMATION AND ANEMIA

by I. Yu. Pchelin, R. A. Gapeshin, N. V. Hudiakova, V. K. Bayrasheva
Published 2016-11-01

Direct comparison of cardioprotective effects of necroptosis inhibitors against global ischemia-reperfusion in the isolated rat heart

by Yu. V. Dmitriev, S. M. Minasian, V. K. Bayrasheva, E. A. Demchenko, M. M. Galagudza
Published 2018-01-01

DERMATOLOGIC DISORDERS IN TRANSGENDER PATIENTS: ACNE, KELOID SCARS, PSEUDOFOLLICULITIS, MELASMA

by V. K. Bayrasheva, O. G. Yushkantseva, E. A. Kosenko, M. S. Boronina, А. E. Egorova
Published 2020-07-01

INTERLEUKIN-6 AND DIABETIC NEPHROPATHY: PATHOGENIC INTERCONNECTIONS, TARGETS FOR NEPHROPROTECTION

by I. Yu. Pchelin, V. K. Bayrasheva, A. N. Shishkin, V. N. Vasilkova, N. V. Hudiakova
Published 2017-12-01

ASSESSMENT OF SODIUM-GLUCOSE CO-TRANSPORTER INHIBITOR IN COMBINATION WITH INSULIN ON METABOLIC PARAMETERS AND RENAL MORPHOFUNCTIONAL CHANGES IN RATS WITH EXPERIMENTAL DIABETES MELL...

by D. A. Lebedev, N. P. Likhonosov, Т. P. Tuchina, V. K. Bayrasheva, A. Yu. Babenko
Published 2017-11-01

EXPERIMENTAL MODELS OF ALIMENTARY OBESITY IN RATS

by V. K. Bayrasheva, I. Y. Pchelin, A. E. Egorova, V. N. Vasilkova, O. V. Kornyushin
Published 2019-11-01

Mechanisms and clinical significance of nephroprotective action of sodium-glucose cotransporter 2 inhibitors

by I. Y. Pchelin, V. N. Vasilkova, A. N. Shishkin, V. K. Bayrasheva, N. V. Hudiakova
Published 2019-01-01

DIAGNOSTIC AND PROGNOSTIC VALUES OF B-TYPE NATRIURETIC PEPTIDES AND N-TERMINAL FRAGMENT BRAIN NATRIURETIC PEPTIDES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISE...

by V. N. Vasilkova, I. Yu. Pchelin, V. K. Bayrasheva, T. V. Mokhort, A. P. Naumenka, N. A. Filiptsova
Published 2018-02-01

NEW PERSPECTIVE FOR THE USE OF SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN DIABETES MELLITUS

by V. K. Bayrasheva, I. Yu. Pchelin, A. N. Arefjeva, P. A. Andoskin, V. N. Vasilkova, D. A. Lebedev, S. G. Chefu
Published 2017-05-01

PROSPECTS OF NEPHROPROTECTION AGAINST TYPE 2 DIABETES USING THE DPP-4 INHIBITOR VILDAGLIPTIN

by V. K. Bayrasheva, A. Y. Babenko, A. A. Bayramov, S. G. Chefu, I. S. Shatalov, I. Y. Pchelin, A. N. Arefieva, E. N. Grineva
Published 2017-12-01

EVALUATION OF THE LEVELS OF FIBROBLAST GROWTH FACTOR (FGF-23) AND INFLAMMATION MARKERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE

by V.M. Vasilkova, T.V. Mokhort, V.K. Bayrasheva, L.E. Korotaeva, Yu.I. Yarets, О.N. Shestovets, Ya.A. Borovets, E.P. Naumenko
Published 2020-04-01